The dragon effect is getting brighter in the domestic drug sector. Over 100 Chinese pharma manufacturers have lined up major India expansion plans via joint ventures, strategic alliances, research collaborations and wholly owned subsidiaries.

The major Chinese pharmaceutical and allied industry players looking at Indian opportunities include A H A International Co, Anhui Biochem Pharm Co, Asahi-Penn Chemical Co, Chengdu Nanxang Biochemical Products Co, CNSC Fortune Way Company, Dongying Tiandong Biochemical Industry Co, Chemwerth Inc, Gansu Xuejing among others.

The Chinese pharmaceutical industry, which has been keen to explore the overseas markets with only consumer oriented business strategies till now, has now realized the importance of Indian synergies in terms of formulation capabilities, service outsourcing strengths as well as market exploration.

Leading pharma players in the Chinese market such as Hebei Changshan Biochemical Pharmaceutical Co, Jiangsu Guotai Intl Group, Kaifeng Pharmaceutical (Group) Co, North China Pharmaceutical Victor Co, Shandong Baayuan Chemical, Shanghai Jinhe Bio-Technology Co are also learnt to have initiated strategic talks with Indian companies.

According to sources, at least 50 odd Chinese companies are currently in talks with Indian pharmaceutical formulation companies, R&D organisations and allied industry players. And there are other 25 to 30 units from the Chinese active pharmaceutical ingredients sector and pharmaceutical machinery sectors who have also sounded their plans for forming joint ventures and business collaborations with Indian industry.

Most of these Chinese companies are participating in the forthcoming CPhI India, which is being held in Mumbai.

Source:佚名